Strontium ranelate: A new treatment for postmenopausal osteoporosis with a dual mode of action |
| |
Authors: | Jean-Yves Reginster Nathalie Sarlet Eric Lejeune Lorenzo Leonori |
| |
Institution: | (1) Bone and Cartilage Metabolism Research Unit, CHU Centre-Ville, Policliniques L. BRULL, Quai Godefroid Kurth 45 (9ème étage), 4020 Liege, Belgium |
| |
Abstract: | In vitro, strontium ranelate increases collagen and noncollagen protein synthesis by mature osteoblast-enriched cells. Its
effects on bone formation were confirmed as the drug enhanced preosteoblastic cell replication. In the isolated osteoclast,
preincubation of bone slices with strontium ranelate-induced dose-dependent inhibition of the bone-resorbing activity of treated
rat osteoclast. Strontium ranelate dose-dependently inhibited preosteoclast differentiation. Its effect in postmenopausal
women with established osteoporosis was assessed during an international, prospective, double-blind, randomized, placebo-controlled
phase 3 program comparing strontium ranelate 2 g daily with placebo. The 3-year analysis of the phase 3 study, Spinal Osteoporosis
Therapeutic Intervention, evaluating the effect of strontium ranelate 2 g/day on vertebral fracture rates, revealed a significant
41% reduction in the relative risk of patients experiencing new vertebral fracture with strontium ranelate over 3 years. A
second phase 3 study showed a significant reduction in the relative risk of experiencing a nonvertebral fracture in the group
treated with strontium ranelate over 3 years. These results show that strontium ranelate is a new, effective, and safe treatment
for vertebral and hip osteoporosis, with a unique mode of action, increasing bone formation and decreasing bone resorption
leading to a rebalance of bone turnover in favor of bone formation. |
| |
Keywords: | |
本文献已被 PubMed SpringerLink 等数据库收录! |
|